Table 1 Characteristics of BCBM patients (n = 445)
Parameter | Category | Overall |
|---|---|---|
Treatment era | 2008–2014 | 249 (56.0%) |
2015–2018 | 196 (44.0%) | |
Breast GPA score | 0.0–1.0 | 103 (23.1%) |
1.5–2.0 | 182 (40.9%) | |
2.5–3.0 | 141 (31.7%) | |
3.5–4.0 | 19 (4.3%) | |
Histological type (primary breast cancer) | Ductal | 371 (94.9%) |
Lobular | 8 (2.0%) | |
Other | 12 (3.1%) | |
Missing | 54 | |
Time from diagnosis of breast cancer to recurrence | Median (range) | 22 (0–256) |
≤ 24 months | 248 (55.7%) | |
> 24 months | 197 (44.3%) | |
Time from diagnosis of breast cancer to brain metastasis | Median (range) | 35 (0–273) |
≤ 24 months | 136 (30.6%) | |
> 24 months | 309 (69.4%) | |
KPS at diagnosis of brain metastasis | ≤ 60 | 95 (21.3%) |
70–80 | 314 (70.6%) | |
90–100 | 36 (8.1%) | |
Tumor subtype (primary breast cancer) | HR-/HER2- | 106 (24.9%) |
HR+/HER2- | 128 (30.1%) | |
HR−/HER2+ | 90 (21.2%) | |
HR+/HER2+ | 101 (23.8%) | |
Missing | 20 | |
Age at diagnosis of brain metastasis (years) | Median (range) | 52 (28–81) |
≥ 60 | 94 (21.1%) | |
< 60 | 351 (78.9%) | |
Number of brain metastasis | Multiple lesions | 301 (67.6%) |
Single lesion | 144 (32.4%) | |
Extracranial disease | Yes | 371 (83.4%) |
No | 74 (16.6%) | |
Extracranial metastatic sites (not mutually exclusive) | Liver | 130 |
Lung | 222 | |
Bone | 205 | |
Lymph nodes | 200 | |
Breast or chest wall | 41 | |
Serous membrane effusion | 46 | |
Adrenal gland | 13 | |
Othera | 8 | |
Number of involved organs | ≤ 3 | 198 (44.5%) |
> 3 | 247 (55.5%) | |
Number of metastatic lesions | ≤ 5 | 113 (25.4%) |
> 5 | 332 (74.6%) | |
Asymptomatic brain metastases | Yes | 154 (35.0%) |
No | 286 (65.0%) | |
Missing | 5 | |
Local therapy after brain metastasis | Surgery ± WBRT/SRS | 30 (6.9%) |
SRS alone | 47 (10.9%) | |
WBRT alone | 261 (60.4%) | |
WBRT + 3DCRT/SRS | 86 (19.9%) | |
No local therapy | 8 (1.9%) | |
Missing | 13 | |
Salvage local therapies | No | 397 (89.2%) |
Yes | 48 (10.8%) | |
Chemotherapy | With Capecitabine | 184 (45.0%) |
Without Capecitabine | 144 (35.2%) | |
No chemotherapy | 81 (19.8%) | |
Missing | 36 | |
Anti-HER2 therapy | Trastuzumab ± Pertuzumab | 48 (10.8%) |
TKI(Pyritinib/Lapatinib) ± Trastuzumab | 97 (21.9%) | |
Other | 3 (0.7%) | |
HER2 + without anti-HER2 therapy | 40 (9.0%) | |
HER2- without anti-HER2 therapy | 255 (57.6%) | |
Missing | 2 | |
Endocrine therapy | Tamoxifen | 6 (1.3%) |
AI ± OFS | 43 (9.7%) | |
AI + CDK4/6 inhibitor ± OFS | 9 (2.0%) | |
Other | 13 (2.9%) | |
HR + without endocrine therapy | 209 (47.0%) | |
HR- without endocrine therapy | 165 (37.1) |